Background-Angina in patients with coronary artery disease is associated with worse quality of life; however, the relationship between angina frequency and resource utilization is unknown. Methods and Results-Using data from the MERLIN-TIMI 36 trial, we assessed the association between the extent of angina after an acute coronary syndrome (ACS) and subsequent cardiovascular resource utilization among 5460 stable outpatients who completed the Seattle Angina Questionnaire at 4 months after an ACS and who were then followed for an additional 8 months. Angina frequency was categorized as none (score, 100; 2739 patients), monthly (score, 61 to 99; 1608 patients), weekly (score, 31 to 60; 854 patients), and daily (score, 0 to 30; 259 patients). Multivariable regression models evaluated the association between angina frequency and overall costs attributable to cardiovascular hospitalizations, outpatient visits and procedures, and medications. As compared with no angina, overall costs increased in a graded fashion with higher angina frequency-no angina, $2928 (reference); monthly angina, $3909 (adjusted relative cost ratio, 1.29; 95% CI, 1.21 to 1.39); weekly angina, $4558 (adjusted relative cost ratio, 1.52; 95% CI, 1.48 to 1.67); and daily angina, $6949 (adjusted relative cost ratio, 2.32; 95% CI, 2.01 to 2.69; P for trend Ͻ0.001). Differences in costs were attributable primarily to higher rates of ACS hospitalization and coronary revascularization among patients with more severe angina. Conclusion-Among stable outpatients after ACS, a direct graded relationship was found between higher angina frequency and healthcare costs. As compared with patients without angina, patients with daily angina had a Ͼ2-fold increase in resource utilization and incremental costs of $4000 after 8 months of follow-up. (Circ Cardiovasc Qual Outcomes. 2009;2:344-353.)
D espite an expanding number of medical and interventional technologies to reduce myocardial ischemia, chronic angina remains a major public health problem that affects more than 9 million Americans. 1 In the setting of acute coronary syndromes (ACS), more aggressive use of cardiac catheterization, improved stent platforms, and more effective antiplatelet therapies have led to improved outcomes in recent years. Nonetheless, a substantial proportion of patients continue to experience angina after hospital discharge. 2 Despite its frequency, little is known regarding the extent to which persistent angina among patients with chronic coronary artery disease after ACS is associated with increased utilization and costs.
Patient-centered health status, which measures patients' symptoms, function, and quality of life, is steadily gaining acceptance as a clinically relevant outcome of cardiovascular care and has been included with greater frequency as an end point in clinical trials. [3] [4] [5] [6] [7] [8] Although generic quality-of-life assessments (such as the SF-36) have been used, disease-specific instruments such as the Seattle Angina Questionnaire (SAQ) have been shown to be more sensitive in fully capturing patient-centered health status among patients with coronary artery disease. 9, 10 Although the SAQ has previously been shown to be associated with mortality and morbidity in patients with chronic coronary artery disease, 11, 12 the magnitude of the association between persistent angina and both future resource utilization and costs has not been described. This is, in part, because of the challenges in obtaining reliable estimates of symptoms from prior clinical trial and administrative data sources.
Historically, third-party payers have been reluctant to emphasize patient-centered outcomes because their value has not been readily apparent, despite their endorsement as important metrics of healthcare quality by professional soci-
WHAT IS KNOWN
• A substantial proportion of patients continue to experience angina after hospital discharge for an acute coronary syndrome, which is associated with worse quality of life.
WHAT THE STUDY ADDS
• As compared with patients without angina, patients with daily angina had a Ͼ2-fold increase in resource utilization and incremental costs of $4000 after 8 months of follow-up. • Differences in utilization were accounted for by higher rates of rehospitalization for acute coronary syndrome or coronary revascularization in patients with more frequent angina. • These findings underscore the potential use of patient-reported health status to identify patients that may benefit from intensive disease management and as a clinically meaningful end point in clinical trials. • The cost estimates in this article can provide a framework for understanding the potential economic impact of current or future therapies aimed at reducing the burden of angina.
eties. 13, 14 Identifying that patients with more frequent angina also incur greater healthcare costs may provide an incentive for third-party payers to promote the study of disease management programs in reducing costs 15 and engage clinicians to be more proactive in identifying highly symptomatic patients and intensifying their medical therapies. Moreover, demonstrating a meaningful gradient in costs would further support the use of patient-centered health status assessments as end points in clinical trials and provide cost estimates critical to policymakers and researchers for informed decision making. Accordingly, we examined the relationship between angina frequency among stable outpatients with coronary artery disease and the incidence of subsequent hospitalizations and healthcare costs among participants in the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation ACS (MERLIN)-TIMI 36 trial. 16, 17 Because of the detailed clinical and healthcare resource use information collected, measurements of patient-centered health status, and close trial follow-up, MERLIN-TIMI 36 represented an ideal opportunity to address these existing gaps in knowledge.
Methods

Study Population
MERLIN-TIMI 36 was a multinational, multicenter, placebocontrolled, randomized clinical trial that evaluated the effect of ranolazine, an antianginal medication, in 6560 patients hospitalized with non-ST-elevation ACS between October 2004 and May 2006. Eligible patients had symptoms consistent with myocardial ischemia at rest lasting Ն10 minutes within the previous 48 hours and had at least one high-risk indicator: elevated biomarkers of myocardial necrosis, ST depression on ECG, diabetes mellitus, or a TIMI risk score of Ն3. Further inclusion and exclusion criteria for the trial have been described previously. 16 Because we were interested in examining the association between angina frequency and resource utilization in outpatients, we limited this analysis to all subjects with a 4-month follow-up assessment after the index hospitalization. As a result, we excluded 190 subjects who died before the baseline assessment, 508 subjects who were lost to follow-up within MERLIN-TIMI 36, and 402 subjects who did not complete the 4-month questionnaire. Thus, our final study cohort comprised 5460 patients, of whom 3341 (61%) lived in European countries; 798 (15%) were from North America (487 [9%] from the United States); and 1321 (24%) were from Russia, Israel, or Africa. Institutional Research Board approval was obtained at all participating centers, and informed consent was obtained from all patients for baseline and follow-up assessments.
Angina Assessment
Four months after hospitalization for ACS, patients were assessed for angina with the SAQ, a reliable and valid instrument that comprises 5 domains that measure unique dimensions of health status and quality of life among patients with coronary disease. 9, 10 For this study, we were interested primarily in the angina frequency domain, which quantifies the frequency and burden of angina over the preceding 4 weeks. Scores for this domain range from 0 to 100 in 10-point increments, with higher scores indicating less angina frequency. Based on prior work, angina frequency was categorized as none (SAQ score, 100), monthly (SAQ score, 61 to 99), weekly (SAQ score, 31 to 60), and daily (SAQ score, 0 to 30). 18 Because MERLIN-TIMI 36 was a multinational clinical trial, country-specific instruments were used for the assessment of angina. We used culturally and linguistically appropriate translations of the SAQ, according to the methodology and processes of the Mapi Research Institute (www.mapi-research.fr/index.htm), including review of the SAQ translation by clinicians and patients within each country before their use. Details on the translation process for the SAQ are available at www.cvoutcomes.org/faqs/3030#3174.
Healthcare Resource Use Assessment
Information regarding cardiovascular hospitalizations, outpatient procedures and visits, and medications were prospectively collected at each follow-up visit. Routine follow-up occurred every 4 months for a total of 8 months (ie, 12 months from the initial ACS hospitalization, which was the median trial follow-up period), after which time patients were censored to avoid incomplete cost assessments. Cardiovascular hospitalizations included admissions for ACS, revascularization procedures, congestive heart failure, valvular disease, arrhythmias, and peripheral vascular disorders. Hospitalizations related to clinical trial end points were adjudicated by an independent events committee and represented Ͼ80% of all cardiovascular hospitalizations in the study. For all cardiovascular hospitalizations (both adjudicated and nonadjudicated), information was collected regarding admitting diagnoses, procedures, and surgeries performed during the hospitalization. Information regarding noncardiovascular hospitalizations was also prospectively collected, but these hospitalizations were not included in these analyses because their frequency was rare (3.1%) and because they were distributed evenly among the angina frequency groups. We also excluded rehabilitation and skilled nursing home stays because of the substantial variation across countries, where the use of these resources and length of stays tend to be determined more by the medical "culture" of the country than by the clinical status of the patient. Additionally, we did not assign societal costs attributable to death because the mortality rate of the population during the study period was low (90 patients, 1.6% of the population).
Costing Methods
Costs were assessed from the perspective of the US healthcare system in 2005 dollars according to standard methods for multinational clinical trials. 19 To determine the cost associated with cardiovascular hospitalizations, an investigator blinded to patient characteristics, including their frequency of angina and treatment group, assigned diagnosis-related groups (DRGs) to each hospitalization during the follow-up period. Costs for each DRG were estimated from average Medicare reimbursement rates obtained from the Medicare Part A data file, 20 and professional costs were calculated as a percentage share of DRG. 21 Similarly, for outpatient utilization, an investigator blinded to patient characteristics and treatment group coded outpatient procedures and visits and assigned a cost based on the Medicare fee schedule. Medication costs were determined based on average wholesale prices from the Drug Topics Red Book, taking a weighted average of the three most frequently used medications in each medication class and using the most commonly prescribed dose for each medication. 22
Statistical Analysis
The primary objective of the study was to quantify the magnitude of the difference in overall cardiovascular costs by angina frequency. Baseline characteristics by angina frequency class were compared using the Mantel-Haenszel trend test for categorical variables and a linear trend test for continuous variables. The relationship between angina frequency and rates of subsequent cardiovascular hospitalization was then evaluated with multivariable Cox regression models, adjusted for enrollment country, sociodemographic factors (age, sex, race, education, living situation), comorbidities (hypertension, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dyslipidemia, prior myocardial infarction [MI], prior percutaneous coronary intervention [PCI], prior coronary artery bypass graft surgery [CABG], diabetes mellitus, smoking status, body mass index), severity of index ACS event (infarction versus unstable angina, TIMI risk score 23 ), treatment during index hospitalization (early invasive strategy, PCI, CABG), and clinical variables at the 4-month follow-up (interval MI; interval revascularization; systolic blood pressure; heart rate; use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, ␤-blockers, calcium channel blockers, clopidogrel, longacting nitrates, statins, warfarin, ranolazine).
We then explored the relationship between angina frequency and costs using generalized linear models, which account for nonnormality of data by using a ␥ distribution with a log-link function and yields an estimate of the multiplicative effect of covariates on costs. Initial unadjusted models examined the bivariate relationship between angina frequency and resource utilization. Multivariable models then assessed the magnitude of the relationship of angina frequency with costs, adjusting for the study covariates described above. All covariates were retained in the final model regardless of statistical significance, and potential interactions with angina frequency were examined. Finally, to determine whether cost differences were attributable primarily to differences in rates of coronary revascularization before the 4-month time point, we constructed models separately among those patients who did and did not undergo coronary revascularization with either PCI or CABG during the index ACS hospitalization or during the interval period before the 4-month baseline assessment.
The null hypothesis for all analyses was evaluated at a 2-sided significance level of 0.05 with 95% CI. All statistical analyses were performed using SAS for Windows version 9.1 (SAS Institute Inc) and R version 2.6.1. 24
Results
At 4 months after ACS, no angina was reported in 2739 (50.2%) patients, whereas monthly angina was reported in 1608 (29.5%), weekly angina in 854 (15.6%), and daily angina in 259 (4.7%) patients. Baseline clinical and sociodemographic characteristics of the study population, stratified by angina frequency, are shown in Table 1 . Patients with greater angina frequency were more likely to be female and from Russia; have a history of prior MI and prior revascularization at the time of their initial ACS event; and have coexisting diabetes mellitus, hypertension, dyslipidemia, and congestive heart failure. They were more likely to have had higher TIMI risk scores at the time of their ACS event but were less likely to have been treated with an early revascu-larization strategy or to undergo PCI or CABG during the index hospitalization for ACS. At the 4-month follow-up visit, patients with greater angina frequency were more likely to be taking antianginal medications but were less likely to be taking clopidogrel or statins.
Inpatient Hospitalizations
In unadjusted analyses, higher angina frequency was associated with an increased risk of cardiovascular hospitalization over the following 8 months (no angina, 9.9%; monthly angina, 12.6%; weekly angina, 13.5%; and daily angina, 20.1%; P for trend Ͻ0.001; Figure 1 ). Patients with higher angina frequency were more likely to be hospitalized for recurrent ACS (no angina, 3.8%; monthly angina, 6.4%; weekly angina, 8.5%, and daily angina, 16.2%; P for trend Ͻ0.001) and for coronary revascularization (no angina, 3.2%; monthly angina, 6.0%; weekly angina, 7.3%; and daily anginaϭ12.0%; P for trend Ͻ0.001). After adjusting for demographic and clinical factors, higher angina frequency was a strong predictor of subsequent cardiovascular hospitalization (no angina [reference group]; monthly angina: hazard ratio [HR], 1.32; 95% CI, 1.09 to 1.59; weekly angina: HR, 1.43; 95% CI, 1.14 to 1.80; and daily angina: HR, 2.16; 95% CI, 1.60 to 2.89; P for trend Ͻ0.001).
Resource Utilization
In unadjusted analyses, a graded relationship was observed between angina frequency and inpatient resource utilization ( Table 2) . Patients with no angina incurred the lowest inpatient costs during follow-up ($1259) as compared with those with monthly angina ($2252), weekly angina ($2898), and daily angina ($5129); P for trend Ͻ0.001. This difference in inpatient costs was largely attributable to higher rates of hospitalization for ACS and coronary revascularization among patients with greater angina frequency, which was consistent throughout each follow-up month (Figure 2) . Similarly, outpatient costs were greater among those with higher angina frequency, although the differences were not as large. Finally, there were no observed differences in overall medication costs between the angina frequency groups, although patients with higher angina frequency were more likely to use antianginal medications but were less likely to use statins and clopidogrel ( Table 2) .
When inpatient, outpatient, and medication costs were aggregated, as compared with patients with no angina ($2928), total healthcare costs increased in a stepwise fashion for patients with monthly angina ($3909), weekly angina ($4558), and daily angina ($6949); P for trend Ͻ0.001. After multivariable adjustment, a graded relationship was seen between higher angina frequency and healthcare costs, with a Ͼ2-fold increase in costs and an absolute difference of Ͼ$4000 among patients with daily angina as compared with those without angina (no angina [reference group; costs of $2928]; monthly angina: relative cost ratio, 1.29; 95% CI, 1.21 to 1.39; weekly angina: relative cost ratio, 1.52; 95% CI, 1.48 to 1.67; daily angina: relative cost ratio, 2.32; 95% CI, 2.01 to 2.69; all comparison PϽ0.001; Table 3 ). This graded relationship was found to be similar across geographical regions within MERLIN-TIMI 36 ( Table 4 ). In addition, although absolute costs decreased over time for all groups, the relative cost ratios were not significantly different be- tween the 2 4-month periods of follow-up (see online-only Data Supplement for time trend analysis). Other factors independently associated with increased healthcare costs included male sex, a history of prior MI, diabetes mellitus, peripheral vascular disease, and higher TIMI risk score during the index hospitalization. Surgical revascularization during the index ACS hospitalization and advanced age were associated with lower healthcare costs during the follow-up period.
Because costs in our study were strongly influenced by subsequent hospitalizations for ACS and revascularization, we repeated these analyses separately among those patients with or without coronary revascularization (PCI or CABG) either during the index ACS hospitalization or during the interval before the 4-month baseline assessment. These analyses demonstrated that the relative association between angina frequency and healthcare costs incurred after the 4-month assessment remained consistent regardless of whether revascularization had been performed beforehand (Figure 3 ), although absolute differences in costs were smaller in patients who had not been revascularized ( Table 5 ).
Discussion
We found and quantified the direct graded relationship between patient-reported angina frequency and subsequent healthcare utilization among stable outpatients with a recent ACS. As compared with patients without angina, patients with daily angina had a Ͼ2-fold increase in resource utilization and incremental costs of $4000 after 8 months of follow-up. Differences in costs for patients with weekly or monthly angina were also significant as compared with the no-angina reference group, although the absolute cost differences were more modest. Differences in utilization were attributable primarily to hospitalizations for recurrent ACS or coronary revascularization. Importantly, we found that the relationship between angina frequency and costs remained consistent among patients who had and who had not undergone coronary revascularization after their ACS event, which suggests that the increased costs in the higher angina frequency groups could not be explained simply by differential rates of baseline revascularization. Notably, the impact of angina frequency on healthcare costs was comparable with or greater than that of other covariates in our analysis, thus underscoring the incremental clinical importance of patientreported symptoms compared with both traditional clinical measures and risk factors. Collectively, these findings highlight the magnitude of resource utilization differences by angina frequency in stable outpatients with coronary artery disease and underscore the potential use of patient-reported health status by third-party payers and clinicians to identify patients for intensive disease management and as a clinically meaningful end point in clinical trials.
Our study adds importantly to previous studies that have examined the prognostic impact of the SAQ among patients Country of enrollment and medication use were also included in all models. *Indicates the time period from index hospitalization to the 4-month follow-up. †Per 10-unit increase.
with chronic coronary disease. Spertus and colleagues have previously reported that among male veterans, the SAQ scale is prognostic of future ACS hospitalizations 12 ; however, this association has not been validated in women or in the contemporary era of drug-eluting stents and antiplatelet therapies. Moreover, the extent to which persistent angina is associated with increased healthcare costs has not been previously described because of the paucity of detailed clinical and administrative sources with both health status and utilization data. The MERLIN TIMI-36 trial is the largest clinical trial to date to assess health status among patients with ischemic heart disease, and it represents a unique opportunity to quantify the magnitude of the association between chronic angina and healthcare utilization. In this contemporary trial, which used modern invasive techniques, improved stent platforms, and dual antiplatelet regimens, persistent or recurrent angina after hospitalization for an ACS remained common, with nearly half of all patients experiencing angina 4 months after the index hospitalization and 1 in 5 patients reporting symptoms at least weekly. The prevalence of residual angina in this high-risk non-ST-elevation ACS population was higher than reported previously in the post-MI population 2 and is likely attributable to the inclusion of subgroups (unstable angina and non-ST-elevation MI) within MERLIN-TIMI 36 known to have higher rates of residual angina. 25 We found that persistent angina after an ACS was associated with a plausible and sizable gradient of risk for increased cardiovascular hospitalizations and incremental costs of approximately $125 (monthly angina) to $500 (daily angina) for each month of follow-up. These increased costs are substantial and are comparable with the findings of a recent analysis of resource utilization among heart failure patients within the EPHESUS trial, which found that, as compared with patients with good heart failure health status, patients with the worst heart failure health status had incremental costs of $575 per month. 26 Our findings highlight the need for heightened surveillance for angina after ACS and suggest that interventions that have the potential to effectively reduce symptoms, including disease management programs that prospectively survey for and treat angina, could potentially reduce both morbidity and healthcarerelated costs.
Clinical and Policy Implications
The degree to which angina burden affects healthcare costs is relevant to clinicians, health economists, and policymakers. As mortality associated with coronary artery disease continues to decrease, there has been a shift in focus toward the effects of chronic coronary artery disease on both public health and patients' quality of life. Our findings underscore the need for clinicians to assess the health status of patients with coronary artery disease to better prognosticate future morbidity and resource utilization and to help calibrate the intensity of therapy. It is interesting to note that in our study population, patients with the most frequent angina were also the least likely to be treated with statins and thienopyridines.
Although it may seem intuitive that patients with more angina would consume more medical resources, the precise magnitude of this effect has yet to be established. Thus, our results provide contemporary estimates of the magnitude of medical resource utilization and healthcare costs associated with persistent angina, which are critical to policymakers for informed decision making and researchers for decision analysis. There has also been a recent surge of new therapeutic options for treating chronic angina, including novel medications, [27] [28] [29] new revascularization techniques and stent technologies, 30, 31 transmyocardial laser revascularization, 32, 33 enhanced external counterpulsation, 34, 35 and even autologous stem cell implantation. 36 However, knowledge about how best to allocate these costly treatments is lacking. In this context, our findings can provide a framework for understanding the potential economic impact of current or future therapies aimed at reducing the burden of angina.
Study Limitations
Our study should be interpreted in the context of the following limitations. Although a cost analysis based on data from a multinational trial but carried out from a single country perspective is not uncommon, results from such an analysis may be biased if there is significant heterogeneity in resource use (eg, different thresholds for hospitalization) between countries included in the trial. 19 However, when we examined the relative cost ratios of healthcare costs by angina frequency class across geographic regions, we did not find that they differed meaningfully. Median follow-up in MERLIN-TIMI 36 was for 8 months after the 4-month follow-up; therefore, our findings regarding the relationship between angina frequency and absolute and relative costs may not apply beyond this time period. Although overall rates of death were low in our study, they were higher among those with greater angina frequency (none, 1.1%; monthly, 1.4%; weekly, 2.9%; and monthly, 5.0%). Because our study did not account for indirect costs attributable to death and lost productivity, we have likely underestimated the true societal costs from recurrent angina after ACS. We also did not have detailed information regarding patients' insurance status for medical care. However, given that the majority of study participants lived in countries with publicly supported healthcare, the impact on our findings is likely to have been minimal. Because one-third of patients did not undergo coronary angiography in MERLIN-TIMI 36, we could not adjust for the severity of coronary atherosclerosis. However, adjustment for coronary anatomy, which may be the underlying cause of angina in the majority of patients, would have led to inappropriate overparameterization in our models. Although our findings suggest an association between those with greater angina frequency and higher costs, whether intensified disease management programs in these high-risk patients can reduce costs remains to be established. Finally, although we were able to adjust for a large number of sociodemographic, clinical, and medication variables that were meticulously collected in a clinical trial setting, there exists the potential for residual confounding in our analyses.
Conclusions
Among stable outpatients after an ACS, residual angina was associated with a graded risk for both cardiovascular hospitalizations and increased resource utilization, with incremental costs exceeding $4000 over 8 months of follow-up among those with daily angina. These data support the use of patient health status as a meaningful end point in clinical trials of patients with ischemic heart disease, provide cost estimates for policymakers for decision making, and may help identify patients who are most likely to benefit from intensified disease management. Data are presented as meanϮSD (US $).
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